Abbott Laboratories
NYSE:ABT
Intrinsic Value
The intrinsic value of one
ABT
stock under the Base Case scenario is
94.26
USD.
Compared to the current market price of 111.08 USD,
Abbott Laboratories
is
Overvalued by 15%.
The Intrinsic Value is calculated as the average of the two valuation methods:
Fundamental Analysis
ABT Profitability Score
Profitability Due Diligence
Abbott Laboratories's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
Score
Abbott Laboratories's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
ABT Solvency Score
Solvency Due Diligence
Abbott Laboratories's solvency score is 74/100. The higher the solvency score, the more solvent the company is.
Score
Abbott Laboratories's solvency score is 74/100. The higher the solvency score, the more solvent the company is.
Balance Sheet Decomposition
Abbott Laboratories
ABT Capital Structure
Abbott Laboratories
| Market Capitalization | 194B USD | |
| Total Debt | 15.3B USD | |
| Minority Interest | 209M USD | |
| Preferred Equity | 0 USD | |
| Cash and Equivalents | 9.6B USD | |
| Short-Term Investments | 313M USD | |
| Enterprise Value | 199B USD | |
Wall St
Price Targets
ABT Price Targets Summary
Abbott Laboratories
According to Wall Street analysts, the average 1-year price target for
ABT
is 122.18 USD
with a low forecast of 92.92 USD and a high forecast of 151.2 USD.
Competitive Landscape
ABT Competitors
Abbott Laboratories
ABT Suppliers & Customers
Abbott Laboratories
Abbott Laboratories has 65 key suppliers from 16 countries and 19 industries. The majority of these suppliers are located in the United States of America, with the largest number of suppliers in the Technology industry.
Abbott Laboratories has 17 key customers from 6 countries and 6 industries. The majority of these customers are located in the United States of America, with the largest number of customers in the Health Care industry.
Ownership
ABT Insider Trading
Buy and sell transactions by insiders
During the last 12 months Abbott Laboratories insiders have not bought any shares, and sold 38.7M USD worth of shares. The last transaction was made on Feb 6, 2023 by Karam Sammy (SENIOR VICE PRESIDENT), who sold 457k USD worth of ABT shares.
Shareholder Return
ABT Price
Abbott Laboratories
| Average Annual Return | 25.93% |
| Standard Deviation of Annual Returns | 4.29% |
| Max Drawdown | -32% |
| Market Capitalization | 194B USD |
| Shares Outstanding | 1 743 570 048 |
| Percentage of Shares Shorted | 0.92% |
Company Profile
Abbott Laboratories
Country
Industry
Market Cap
Dividend Yield
Description
Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. The company is headquartered in Abbott Park, Illinois and currently employs 113,000 full-time employees. The firm operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its Established Pharmaceutical Products segment includes gastroenterology products, women’s health products, cardiovascular and metabolic products, pain and central nervous system products and respiratory drugs and vaccines. Its Diagnostic Products segment includes core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion medicine; molecular diagnostics polymerase chain reaction (PCR) instrument systems; point of care systems; rapid diagnostics lateral flow testing products, and informatics and automation solutions. Its Nutritional Products segment includes various forms of infant formula and follow-on formula, adult and other pediatric nutritional products and others.
Contact
IPO
Employees
Officers
The intrinsic value of one
ABT
stock under the Base Case scenario is
94.26
USD.
Compared to the current market price of 111.08 USD, Abbott Laboratories is Overvalued by 15%.
